Today, caBIG® connects the U.S. cancer community including an expanding group of international collaborators including the U.K. and China.
The "connected" cancer community grew last year, as the underlying IT network, caGrid, became more widely accepted in support of collaborative cancer research.
The power of caBIG® derives from its ability to bridge people and knowledge from different fields of cancer research and care. Genomics, proteomics, radiology, clinical research, and other areas of study inform on another, and ultimately inform clinical decision-making.
Researchers are seeking reliable "biomarkers" such as gene expression patterns to help identify cancer subgroups. Such information helps speed the development of targeted therapies to enable physicians to individualize treatment.

